Catherine Duggan led this analysis of markers of obesity (e.g., leptin, glucose, adiponectin, insulin) and risk of progressing to cancer. It was picked up in the AGA Journals Blog by Kristine Novak.

Clin Gastroenterol Hepatol. 2013 Mar 1. pii: S1542-3565(13)00274-7. doi: 10.1016/j.cgh.2013.02.017. [Epub ahead of print]

Association Between Markers of Obesity and Progression From Barrett’s Esophagus to Esophageal Adenocarcinoma.

Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ, Vaughan TL.

Abstract

BACKGROUND & AIMS:  Individuals with Barrett’s esophagus (BE) have an increased risk of developing esophageal adenocarcinoma (EA). Obesity contributes to the development of BE and its progression to cancer. We investigated the roles of obesity-induced hyperinsulinemia and dysregulation of adipokines in these processes.

METHODS:  We measured fasting levels of glucose, insulin, leptin, and adiponectin in 392 patients enrolled in the Seattle Barrett’s Esophagus Study. We calculated homeostatic model assessment scores (a measure of insulin sensitivity) and identified subjects with metabolic syndrome. We evaluated the association between these measures and the risk of EA using Cox regression models adjusted for known risk factors.

RESULTS:  Increasing homeostatic model assessment scores were associated with an increasing risk for EA; the strongest association was observed within the first 3 years after participants entered the study (hazard ratio [HR], 2.45; 95% confidence interval [CI], 1.43-4.1; Ptrend = .001). Leptin level also was associated significantly with an increased risk of EA within 3 years (HR, 2.51; 95% CI, 1.09-5.81; Ptrend = .03) and 6 years (HR, 2.07; 95% CI, 1.01-4.26; Ptrend = .048) of baseline. The level of high-molecular-weight adiponectin had a nonlinear inverse association with risk of EA; the strongest associations were observed in the second tertile (HR, 0.34; 95% CI, 0.14-0.82). Metabolic syndrome was not associated with risk of EA.

CONCLUSIONS:  Among patients with BE, increased levels of leptin and insulin resistance are associated with increased risk for EA, whereas increased levels of high-molecular-weight adiponectin is associated inversely with EA. These biomarkers might be used to determine cancer risk among patients with BE.